Risicofactoren voor cardiovasculaire ziekten (borderline) hypercholesterolemia high cholesterol
Conditions
Interventions
Participants will receive a daily dose of OLECOL or placebo for a period of 8
weeks. Two capsules of OLECOL or placebo have to be ingested every day 30
minutes before the first meal with a glass of
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy individuals, Age: 18-70 years, BMI 25-35 kg/m2, Total cholesterol levels * 5.0 mmol/L.
Exclusion criteria
Exclusion criteria: * History of severe cardiovascular, respiratory, urogenital, gastrointestinal/hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat). Dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological diseases, allergy, major surgery and /or laboratory assessments that might limit participation in or completion of the study protocol. * Diabetes * Use of medication that might have influence on endpoints (e.g. cholesterol lowering medication, hypertensive medication) * Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study in the 180 days prior to this study * Use of antibiotics in the 30 days prior to the start of the study * Use of antioxidants, minerals and vitamin supplements available in pharmacies, drugstores, food markets or in alternative medicine * Pregnancy, lactation * Abuse of products (> 20 alcoholic consumptions per week and drugs) * Smoking * Weight gain or loss (> 3 kg in previous 3 months) * High physical activity (>4.5 hours of running/week) * History of any side effects towards intake of olives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficady parameter is blood lipid profile, as assesed by blood levels of total cholesterol, HDL and LDL cholesterol and triglycerides. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives include the assessment of the effect of OLECOL on lipid peroxidation, platelet aggregation, advanced glycation end-products, blood pressure, liver function, glucose and insulin metabolism, intestinal inflammation, metabolic activity, microbiota composition, and gastrointestinal symptoms. | — |
Countries
Netherlands
Outcome results
None listed